
Febrile Neutropenia - Pipeline Insight, 2025
Description
DelveInsight’s, Febrile Neutropenia - Pipeline Insight, 2025,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Febrile Neutropenia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Febrile Neutropenia: Overview
Neutropenic fever is defined as a single oral temperature greater than or equal to 101 F, or a temperature greater than or equal to 100.4 F for at least an hour, with an absolute neutrophilic count (ANC) of less than 1500 cells/microliter. In severe neutropenia, the absolute neutrophil count (ANC) is less than 500 per microliter, or ANC is expected to decrease below 500 cells/microL in the next 2 hours. Febrile Neutropenia is the most common serious and common complication of cancer therapy. Neutropenic fever is the most common and serious complication associated with hematopoietic cancers or with patients receiving chemotherapeutic regimens for cancer. Neutropenic fever occurs when a neutropenic patient encounters an infectious pathogen. In this immunocompromised state, patients lose or have weakened immunity to fend off infections. The host barriers, such as the mucosal lining of the GI tract or sinuses, may be damaged, leading the host open to invasion from an infectious pathogen.
""Febrile Neutropenia - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Febrile Neutropenia pipeline landscape is provided which includes the disease overview and Febrile Neutropenia treatment guidelines. The assessment part of the report embraces, in depth Febrile Neutropenia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Febrile Neutropenia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
Febrile Neutropenia Emerging Drugs
Further product details are provided in the report……..
Febrile Neutropenia: Therapeutic Assessment
This segment of the report provides insights about the Febrile Neutropenia drugs segregated based on following parameters that define the scope of the report, such as:
Febrile Neutropenia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Febrile Neutropenia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Febrile Neutropenia drugs.
Febrile Neutropenia Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Febrile Neutropenia: Overview
Neutropenic fever is defined as a single oral temperature greater than or equal to 101 F, or a temperature greater than or equal to 100.4 F for at least an hour, with an absolute neutrophilic count (ANC) of less than 1500 cells/microliter. In severe neutropenia, the absolute neutrophil count (ANC) is less than 500 per microliter, or ANC is expected to decrease below 500 cells/microL in the next 2 hours. Febrile Neutropenia is the most common serious and common complication of cancer therapy. Neutropenic fever is the most common and serious complication associated with hematopoietic cancers or with patients receiving chemotherapeutic regimens for cancer. Neutropenic fever occurs when a neutropenic patient encounters an infectious pathogen. In this immunocompromised state, patients lose or have weakened immunity to fend off infections. The host barriers, such as the mucosal lining of the GI tract or sinuses, may be damaged, leading the host open to invasion from an infectious pathogen.
""Febrile Neutropenia - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Febrile Neutropenia pipeline landscape is provided which includes the disease overview and Febrile Neutropenia treatment guidelines. The assessment part of the report embraces, in depth Febrile Neutropenia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Febrile Neutropenia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence R&D Febrile Neutropenia. The therapies under development are focused on novel approaches to treat/improve Febrile Neutropenia.
- In May 2022, BeyondSpring presented new clinical data in the Chemotherapy-Induced Neutropenia.The DUBLIN-3 Phase 3 trial is a randomized, single blinded, active-controlled global trial that enrolled 559 patients with 2nd/3rd line NSCLC, EGFR wild type, with a measurable lung lesion. Patients were treated on a 21-day cycle with an infusion of docetaxel (75 mg/m2 on day 1) and plinabulin (30 mg/m2 on days 1 and 8) vs. docetaxel alone (75 mg/m2, day 1). The primary endpoint was overall survival. Secondary endpoints include ORR, PFS, grade 4 neutropenia, 2 year and 3 year OS rate and quality of life analysis. Plinabulin in combination with docetaxel (DP) showed statistically significant overall survival improvements compared to docetaxel alone (D) for the ITT population (DP: n=278; D: n=281).
Febrile Neutropenia Emerging Drugs
- Plinabulin: BeyondSpring Pharmaceuticals
Further product details are provided in the report……..
Febrile Neutropenia: Therapeutic Assessment
This segment of the report provides insights about the Febrile Neutropenia drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Febrile Neutropenia
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Molecule Type
- Peptides
- Recombinant proteins
- Small molecule
- Product Type
Febrile Neutropenia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Febrile Neutropenia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Febrile Neutropenia drugs.
Febrile Neutropenia Report Insights
- Febrile Neutropenia Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Febrile Neutropenia drugs?
- How many Febrile Neutropenia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Febrile Neutropenia?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Febrile Neutropenia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Febrile Neutropenia and their status?
- What are the key designations that have been granted to the emerging drugs?
- Daewoong Pharmaceutical
- RedHill Biopharma
- Allakos
- Hanmi Pharmaceutical
- Trio Medicines
- Bristol-Myers Squibb
- Fexuprazan
- Ondansetron controlled-release
- Lirentelimab
- HIP 2101
- Netazepide
- Cendakimab
Table of Contents
65 Pages
- Introduction
- Executive Summary
- Febrile Neutropenia: Overview
- What is Febrile Neutropenia?
- Types of Febrile Neutropenia
- Causes
- Epidemiology and Risk Factors
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Febrile Neutropenia– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Fexuprazan: Daewoong Pharmaceutical
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Netazepide: Trio Medicines
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Febrile Neutropenia Key Companies
- Febrile Neutropenia Key Products
- Febrile Neutropenia- Unmet Needs
- Febrile Neutropenia- Market Drivers and Barriers
- Febrile Neutropenia- Future Perspectives and Conclusion
- Febrile Neutropenia Analyst Views
- Febrile Neutropenia Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.